Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer.

Article Details

Citation

Copy to clipboard

van Groeningen CJ, Peters GJ, Pinedo HM

Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer.

Eur J Cancer Clin Oncol. 1989 Jan;25(1):45-9.

PubMed ID

2784100 [ View in PubMed

]

Abstract

Favorable results have been reported for the treatment of advanced colorectal cancer with the combination of 5-fluorouracil (5-FU) and leucovorin (LV). In these investigations the highest response rates were obtained in non-pretreated patients. In the present study, 22 patients with primary or acquired resistance to single-agent 5-FU and documented progressive disease on 5-FU were given a bolus injection of LV at a dose of 200 mg/m2, 1 h prior to a 2 h infusion of 5-FU at a dose of 370-770 mg/m2 on 5 consecutive days, and this was repeated every 3 weeks. Whenever possible the dose of 5-FU was escalated to find the maximum tolerable dose. No objective response was observed. Five patients had short-lasting stable disease. Despite 5-FU dose escalation, toxicity was acceptable. One patient developed 5-FU-related angina pectoris with EKG changes. It is concluded that in the schedule used, combined LV/5-FU treatment is ineffective for patients with 5-FU-resistant advanced colorectal cancer.

DrugBank Data that Cites this Article

Drugs

Duloxetine

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Duloxetine	Sodium-dependent noradrenaline transporter	Protein	Humans	Yes	Inhibitor	Details
Duloxetine	Sodium-dependent serotonin transporter	Protein	Humans	Yes	Inhibitor	Details